Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozurdex vs Ozurdex plus peripheral laser for diabetic macular edema
2016-003870-41Phase 4Recruiting
- Sponsor
- Fundación para la Investigación Biomédica del Hospital Universitario Príncipe de Asturias
- Start
- Jan 2017
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of ozurdex in diabetic macular edema (DME) (2 arms), sponsored by Fundación para la Investigación Biomédica del Hospital Universitario Príncipe de Asturias. Primary endpoint: Corrected visual acuity at 1 year. Started Jan 2017; status: recruiting.
02
Drugs
ozurdex
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2016-003870-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003870-41.